CT and MRI Data Show Improved Progression-Free Survival with Emerging Agent for NETs

MRI and CT data from a clinical trial show an emerging agent significantly improves progression-free survival in gastroenteropancreatic neuroendocrine tumors, per Diagnostic Imaging.

• The study used serial MRI and CT to measure progression-free survival (PFS) as the key efficacy endpoint for an emerging therapeutic agent in gastroenteropancreatic neuroendocrine tumors.
• As a trade news summary, the report provides an overview rather than detailed statistical outcomes; the agent's approval status and trial phase are not specified.

RadPigeon summaries are original and for information only. They are not clinical advice.